1,084 results on '"Geisbert, Thomas W."'
Search Results
2. Monoclonal antibody therapy protects nonhuman primates against mucosal exposure to Lassa virus
3. Thermostable bivalent filovirus vaccine protects against severe and lethal Sudan ebolavirus and marburgvirus infection
4. Ebola vaccine–induced protection in nonhuman primates correlates with antibody specificity and Fc-mediated effects
5. Nonhuman Primate Models for Nipah and Hendra Virus Countermeasure Evaluation
6. Overview of Experimental Vaccines and Antiviral Therapeutics for Henipavirus Infection
7. Therapy for Argentine hemorrhagic fever in nonhuman primates with a humanized monoclonal antibody
8. Therapeutic administration of a cross-reactive mAb targeting the fusion glycoprotein of Nipah virus protects nonhuman primates
9. A Glass-Half-Full Perspective on Negative Data in Ebolavirus Vaccine Studies
10. Oral administration of obeldesivir protects nonhuman primates against Sudan ebolavirus
11. Cooperativity mediated by rationally selected combinations of human monoclonal antibodies targeting the henipavirus receptor binding protein
12. Recombinant vesicular stomatitis virus-vectored vaccine induces long-lasting immunity against Nipah virus disease
13. Broadly neutralizing antibody cocktails targeting Nipah virus and Hendra virus fusion glycoproteins
14. Monoclonal antibody therapy demonstrates increased virulence of a lineage VII strain of Lassa virus in nonhuman primates.
15. Endotheliopathy and Platelet Dysfunction as Hallmarks of Fatal Lassa Fever
16. Establishment of an African green monkey model for COVID-19 and protection against re-infection
17. Marburg and Ravn Viruses Fail to Cause Disease in the Domestic Ferret ( Mustela putorius furo )
18. Efficacy of Human Monoclonal Antibody Monotherapy Against Bundibugyo Virus Infection in Nonhuman Primates
19. Comparative Transcriptomics in Ebola Makona-Infected Ferrets, Nonhuman Primates, and Humans
20. Role of Antibodies in Protection Against Ebola Virus in Nonhuman Primates Immunized With Three Vaccine Platforms
21. Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates
22. Single dose rVSVΔG-JUNVGP vaccine protects guinea pigs against lethal Junin virus challenge
23. Combination therapy protects macaques against advanced Marburg virus disease
24. A single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus
25. Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death
26. The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus
27. Antibody therapy for Lassa fever
28. Marburg and Ravn Viruses (Filoviridae)
29. High-Avidity Anti-Filovirus IgG Elicited Using Protein Subunit Vaccines Does Not Correlate with Protection
30. Revisiting the minimum incubation period of Zaire ebolavirus
31. Animal Models for Henipavirus Research
32. Modelling Marburg Virus Disease in Syrian Golden Hamsters: Contrasted Virulence between Angola and Ci67 strains
33. Perspectives on Advancing Countermeasures for Filovirus Disease: Report From a Multisector Meeting
34. A human monoclonal antibody combination rescues nonhuman primates from advanced disease caused by the major lineages of Lassa virus
35. Use of Single-Injection Recombinant Vesicular Stomatitis Virus Vaccine to Protect Nonhuman Primates Against Lethal Nipah Virus Disease
36. An antibody against the F glycoprotein inhibits Nipah and Hendra virus infections
37. The Host Response to Smallpox: Analysis of the Gene Expression Program in Peripheral Blood Cells in a Nonhuman Primate Model
38. Single-dose VSV-based vaccine protects cynomolgus macaques from disease after Taï Forest virus infection
39. Limited benefit of post-exposure prophylaxis with VSV-EBOV in Ebola virus-infected rhesus macaques
40. Long-term Prophylaxis Against Aerosolized Marburg Virus in Nonhuman Primates With an Afucosylated Monoclonal Antibody
41. Natural History of Nonhuman Primates After Oral Exposure to Ebola Virus Variant Makona
42. A highly attenuated pan-filovirus VesiculoVax vaccine rapidly protects nonhuman primates against Marburg virus and three species of Ebolavirus
43. Pathogenesis of Aerosolized Ebola Virus Variant Makona in Nonhuman Primates
44. Reverse Genetics with a Full-Length Infectious cDNA of Severe Acute Respiratory Syndrome Coronavirus
45. Neutralizing the Threat: Pan-Ebolavirus Antibodies Close the Loop
46. Antibodies from Sierra Leonean and Nigerian Lassa fever survivors cross-react with recombinant proteins representing Lassa viruses of divergent lineages
47. Intranasal exposure of African green monkeys to SARS-CoV-2 results in acute phase pneumonia with shedding and lung injury still present in the early convalescence phase
48. Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment
49. Immune correlates of postexposure vaccine protection against Marburg virus
50. Rational design of universal immunotherapy for TfR1-tropic arenaviruses
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.